Birinapant(CAS: 1260251-31-7)

Birinapant (CAS: 1260251-31-7) is subject to regulatory guidelines under the Globally Harmonized System (GHS) for classification and labeling of chemicals. In the European Union, it is regulated under REACH, and in the United States, it is overseen by the FDA and EPA. Manufacturers and importers must comply with specific documentation, testing, and reporting requirements to ensure safety and environmental protection.

Several alternatives to Birinapant (CAS: 1260251-31-7) exist in synthesis, including other small molecule inhibitors of cystine-glutamate antiporter (CAT-1). Common alternatives include analogs with similar structural modifications and isomers, which can serve as effective substitutes depending on the specific application and desired biological activity.

The market for Birinapant (CAS: 1260251-31-7) is growing due to increasing interest in its potential as a therapeutic agent for various cancers. Research trends indicate a focus on its mechanism of action, efficacy in combination therapies, and further exploration of its role in modulating immune responses. The compound shows promise in preclinical studies and clinical trials, driving market demand and investment.

Waste containing Birinapant (CAS: 1260251-31-7) should be handled by collecting it in appropriate containers, ensuring it is sealed to prevent leaks. For small quantities, incineration or professional waste disposal services are recommended. Environmental protection measures include avoiding direct contact, ensuring proper labeling, and adhering to local and national regulations for hazardous waste disposal to minimize environmental impact.